Neuroprotective Compounds

The text shown here has been derived from the original document's published images via a process of ´optical character recognition (OCR). Due to variations in image quality, and the imperfect nature of OCR process, this text may not be 100% accurate. To view the original published images, please refer to the PDF.


(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

I
(10) International Publication Number

(43) International Publication Date
29 December 2011 (29.12.2011)

P O

WO 2011/163241 A3

PCT

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG,
SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(51) International Patent Classification:
A01N 43/90 (2006.01)
(21) International Application Number:
PCT/US201 1/041265

(22) International Filing Date:
2 1 June 201 1 (21 .06.201 1)

(84) Designated States (unless otherwise indicated, for every
kind o regional protection available): ARIPO (BW, GH,
f
English
(26) Publication Language:
GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG,
ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,
(30) Priority Data:
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
61/356,925
2 1 June 2010 (21.06.2010)
US
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
(71) Applicant (for all designated States except US): GEOR¬
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
GETOWN UNIVERSITY [US/US]; A Congressionally
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
Chartered Institution, of Higher Education, 37th & O
ML, MR, NE, SN, TD, TG).
Streets, N.W., Washington, District of Columbia 20057
Declarations under Rule 4.17 :
(US).
(25) Filing Language:

English

(72) Inventors; and
(75) Inventors/Applicants (for US only): DJAKIEW, Daniel
[US/US]; 1536 Longfellow Street, McLean, Virginia
22101 (US). EL TOUNY, Lara, H. [EG/US]; 4440 Willard Ave., Apt. 417, Chevy Chase, Maryland 20815 (US).
(74) Agent: MCKEON, Tina, Williams; McKeon, Meunier,
Carlin & Curfman, LLC, Suite 900, 817 W . Peachtree
Street NW, Atlanta, Georgia 30308 (US).
(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO,

—

as to applicant's entitlement to apply for and be granted a
patent (Rule 4.1 7(H))

—

as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.1 7(in))

—

o inventorship (Rule 4. 1 7(iv))
f

Published:

—

with international search report (Art. 21(3))

(88) Date of publication of the international search report:
20 March 2014

(54) Title: NEUROPROTECTIVE COMPOUNDS
(57) Abstract: This disclosure relates to compounds that can be utilized to treat a neural injury or disorder. Methods of identifying
and making these compounds are also set forth herein.

INTERNATIONAL SEARCH REPORT

International

application

PCT/US

A .

CLASSIFICATION

O F SUBJECT

IPC(8) - A01 N 43/90,
USPC - 5 14/259.3
According
B.

to International

FIELDS

43/14;

1 1/41265

MATTER

(201 1 .01 )

Patent Classification

(IPC)

o r to both national

classification

and IPC

SEARCHED

Minimum documentation searched (classification
IPC(8): A01N 43/90, 43/14; (201 1.01)
USPC: 514/259.3

system followed

Documentation searched other than minimum documentation
IPC(8): A01N 43/90; A 6 1 31/535, 31/44 (201 1 .01)
USPC: 514/259.3,263.3,229.8,290,437

Electronic data base consulted during the international

by classification

symbols)

to the extent that such documents are included in the fields searched

search (name of data base and, where practicable,

search terms used)

PubWEST;PGPB,
USPT, EPAB, JPAB, GoogleScholar,
ScienceDirect,
Dialog
Biochanin-A Biochanin 4'-Methylgenistein
olmelin Biochanine A Biochanin-A
Genistein
isoflavones
injury neuroprotection
Low-Affinity Nerve Growth Factor Receptor, LNGFR, p75 neurotropfiin receptor,

C.

No.

DOCUMENTS

CONSIDERED
Citation

Category*

p75NTR
p38-MAPK
P38 mitogen-activated

T O B E RELEVANT

o f document,

with indication,

where appropriate,

o f the relevant

passages

Relevant
12-14,

U S 2006/0276393
A 1 (MILBURN
e t al.) 7 December
para[0175]-para[0181],
para[1099],
para[1 153]

2006 (07.12.2006)

Abstract,

23-25

and 34-36

1-3

1-3, 47-50

U S 2008/0064036

A 1 (BRUINZEEL

46-53

U S 2005/0239882

A 1 (KIM e t al.) 2 7 October

U S 2003/0109027

A 1 (MURAKAMI

e t al.) 13 March 2008 (13.03.2008)
2005 (27.10.2005)

e t al.) 12 June 2003

Abstract,

Abstract,

(12.06.2003)

para[0049]

para[0014]

para[0080],

CONTINUED

Further

documents

O N NEXT

are listed in the continuation

Special categories of cited documents:

earlier application or patent but published on or after the international
filing date

L"

document which may throw doubts on priority claim(s) or which is
cited to establish the publication date of another citation or other
special reason (as specified)

O"

document referring to an oral disclosure, use, exhibition
means

P"

document published prior to the international filing date but later than
the priority date claimed
search

201 1 (09.1 1 .201 1)

address o f the ISA/US

Mail Stop PCT, Attn: ISA/US, Commissioner
for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile

No.

Form PC T

SA

10 (second

sheet) (July 2009)

51-52

"T"

E"

and mailing

RNA

□

o f Box C .

later document published after the international filing date or priority
date and not in conflict with the application but cited to understand
the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be
considered novel or cannot be considered to involve an inventive
step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be
considered to involve an inventive step when the document is
combined with one or more other such documents, such combination
being obvious to a person skilled in the art

"&"

document member of the same patent family

document defining the general state of the art which is not considered
to be of particular relevance

o f the international

48-50

SHEET

A"

Date o f the actual completion

46-53

para[0134]

Quann e t al. The p38 MAPK Pathway Mediates Aryl Propionic Acid. Induced Messenger
Stability o f p75NTR in Prostate Cancer Cells. Cancer Res 2007;67:1 1402-1 1410.
Abstract

Name

to claim No.

para[0005],

Culmsee e t al. NERVE GROWTH
FACTOR SURVIVAL
SIGNALING
IN CULTURED
HIPPOCAMPAL
NEURONS
IS MEDIATED
THROUGH
TRKA AND REQUIRES
THE COMMON
NEUROTROPHIN
RECEPTOR
P75. Neuroscience
Vol. 1 15, No. 4 , pp. 1089-1 108, 2002
Abstract

9 November

neural
protein....

or other

Date o f mailing

o f the international

2 5 NOV
Authorized

search report

2011

officer:
Lee W . Young

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 11/41265

Box No. II

Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

□

Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an
extent that no meaningful international search can be carried out, specifically:

Claims Nos.: 4-1 1,15-22,26-33,37-45
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

3.

Box No. Ill

Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

□
□
□

As all required additional search fees were timely paid by the applicant, this international search report covers all searchable
claims.

As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of
additional fees.
As only some of the required additional search fees were timely paid by the applicant, this international search report covers
only those claims for which fees were paid, specifically claims Nos.:

No required additional search fees were timely paid by the applicant. Consequently, this international search report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

□
□

The additional search fees were accompanied by the applicant's protest and, where applicable, the
payment of a protest fee.
*
The additional search fees were accompanied by the applicant's protest but the applicable protest
fee was not paid within the time limit specified in the invitation.
No protest accompanied the payment of additional search fees.

Form PCT/lSA/210 (continuation of first sheet (2)) (July 2009)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 11/41265

C (Continuation).
Category*

DOCUMENTS CONSIDERED

T O BE RELEVANT

Citation o f document, with indication, where appropriate, of the relevant passages

Relevant to claim No.

CONTINUED FROM PRIOR SHEET
A

Nguyen et al. The intracellular genistein metabolite 5,7,3-tetrahydroxyisoflavone
mediates G2-M cell cycle arrest in cancer cells via modulation of the p38 signaling pathway.
Free Radical Biology & Medicine 4 1 (2006) 1225.1239 Abstract

A
Munoz et al. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease.
Neuropharmacology 58 (2010) 561-568 Abstract
A

Sonee et al. The Soy Isoflavone, Genistein, Protects Human Cortical Neuronal Cells from
Oxidative Stress. NeuroToxicology 25 (2004) 885.891 Abstract

A

Schroeter et al. Flavonoids protect neurons from oxidized low-density-lipoprotein-induced
apoptosis involving c-Jun N-terminal kinase (JNK), c-Jun and caspase-3. Biochem. J. (2001)
358, 547-557 Abstract

Form PCT/lSA/210 (continuation of second sheet) (July 2009)

1-3, 12-14, 23-25, 34-36
and 46-53

1-3, 12-14, 23-25, 34-36
and 46-53
1-3, 12-14, 23-25, 34-36
and 46-53

1-3, 12-14, 23-25, 34-36
and 46-53



Sign in to the Lens

Feedback